Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 172

1.

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.

Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC; Alzheimer’s Disease Neuroimaging Initiative.

Nat Commun. 2016 Jun 21;7:11934. doi: 10.1038/ncomms11934.

PMID:
27327500
2.

An autoradiographic evaluation of AV-1451 Tau PET in dementia.

Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, Kantarci K, Boeve BF, Pandey MK, Bruinsma T, Knopman DS, Jones DT, Petrucelli L, Cook CN, Graff-Radford NR, Dickson DW, Petersen RC, Jack CR Jr, Murray ME.

Acta Neuropathol Commun. 2016 Jun 13;4(1):58. doi: 10.1186/s40478-016-0315-6.

3.

MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies.

Labbé C, Heckman MG, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Murray ME, Allen M, Uitti RJ, Wszolek ZK, Smith GE, Kantarci K, Knopman DS, Lowe VJ, Jack CR Jr, Ertekin-Taner N, Hassan A, Savica R, Petersen RC, Parisi JE, Maraganore DM, Graff-Radford NR, Ferman TJ, Boeve BF, Dickson DW, Ross OA.

Alzheimers Dement. 2016 Jun 7. pii: S1552-5260(16)30260-6. doi: 10.1016/j.jalz.2016.05.002. [Epub ahead of print]

PMID:
27287057
4.

A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease.

Liu H, Zhou X, Jiang H, He H, Liu X; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2016 Jun 7;6:26712. doi: 10.1038/srep26712.

5.

Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry.

Graff-Radford J, Lesnick TG, Boeve BF, Przybelski SA, Jones DT, Senjem ML, Gunter JL, Ferman TJ, Knopman DS, Murray ME, Dickson DW, Sarro L, Jack CR Jr, Petersen RC, Kantarci K.

Mov Disord. 2016 May 23. doi: 10.1002/mds.26666. [Epub ahead of print]

PMID:
27214825
6.

MR spectroscopy, APOE genotype, and evolving β-amyloid pathology: What is being detected and when.

Kantarci K, Goldberg TE.

Neurology. 2016 May 10;86(19):1750-1. doi: 10.1212/WNL.0000000000002680. Epub 2016 Apr 15. No abstract available.

PMID:
27164709
7.

Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition.

Kantarci K, Lowe VJ, Lesnick TG, Tosakulwong N, Bailey KR, Fields JA, Shuster LT, Zuk SM, Senjem ML, Mielke MM, Gleason C, Jack CR, Rocca WA, Miller VM.

J Alzheimers Dis. 2016 May 7. [Epub ahead of print]

PMID:
27163830
8.

Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer's pathology.

Savica R, Murray ME, Persson XM, Kantarci K, Parisi JE, Dickson DW, Petersen RC, Ferman TJ, Boeve BF, Mielke MM.

Alzheimers Dement (Amst). 2016;3:43-50.

9.

An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease.

Raman MR, Schwarz CG, Murray ME, Lowe VJ, Dickson DW, Jack CR Jr, Kantarci K.

J Neuroimaging. 2016 May;26(3):264-8. doi: 10.1111/jon.12341. Epub 2016 Mar 28.

PMID:
27017996
10.

Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder.

Boeve BF, St Louis EK, Kantarci K.

Brain. 2016 Apr;139(Pt 4):1005-7. doi: 10.1093/brain/aww030. No abstract available.

PMID:
27012490
11.

Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders.

Mielke MM, Milic NM, Weissgerber TL, White WM, Kantarci K, Mosley TH, Windham BG, Simpson BN, Turner ST, Garovic VD.

Circ Cardiovasc Qual Outcomes. 2016 Feb;9(2 Suppl 1):S70-6. doi: 10.1161/CIRCOUTCOMES.115.002461.

PMID:
26908863
12.

Regional T1 relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure.

Raman MR, Shu Y, Lesnick TG, Jack CR, Kantarci K.

Magn Reson Med. 2016 Feb 17. doi: 10.1002/mrm.26140. [Epub ahead of print]

PMID:
26888162
13.

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.

14.

Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.

Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Jan 15;8:2. doi: 10.1186/s13195-016-0172-3.

15.

Highly adaptive tests for group differences in brain functional connectivity.

Kim J, Pan W; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2015 Oct 22;9:625-39. doi: 10.1016/j.nicl.2015.10.004. eCollection 2015.

16.

Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder.

McCarter SJ, Tippmann-Peikert M, Sandness DJ, Flanagan EP, Kantarci K, Boeve BF, Silber MH, St Louis EK.

Sleep Med. 2015 Dec;16(12):1502-10. doi: 10.1016/j.sleep.2015.07.018. Epub 2015 Sep 14.

PMID:
26611948
17.

Atrial fibrillation, cognitive impairment, and neuroimaging.

Graff-Radford J, Madhavan M, Vemuri P, Rabinstein AA, Cha RH, Mielke MM, Kantarci K, Lowe V, Senjem ML, Gunter JL, Knopman DS, Petersen RC, Jack CR Jr, Roberts RO.

Alzheimers Dement. 2016 Apr;12(4):391-8. doi: 10.1016/j.jalz.2015.08.164. Epub 2015 Oct 23.

PMID:
26607820
18.

Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?

Teipel S, Grothe MJ; Alzheimer´s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):526-36. doi: 10.1007/s00259-015-3222-3. Epub 2015 Nov 10.

PMID:
26555082
19.

MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials.

Hua X, Ching CR, Mezher A, Gutman BA, Hibar DP, Bhatt P, Leow AD, Jack CR Jr, Bernstein MA, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Jan;37:26-37. doi: 10.1016/j.neurobiolaging.2015.09.018. Epub 2015 Oct 19.

20.

A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.

Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Jan;37:208.e1-9. doi: 10.1016/j.neurobiolaging.2015.09.009. Epub 2015 Sep 25.

PMID:
26545630
Items per page

Supplemental Content

Loading ...
Write to the Help Desk